



LMA International NV

30 October 2006

Announcement to the Singapore Exchange concerning a Related Party Transaction

Singapore-listed LMA International N.V. ("LMA"), a global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, announced that it has acquired the intellectual property rights to the LMA Supreme™, the latest generation single use laryngeal mask airway, from Venner Capital SA ("Venner") for US\$4.7 million.

The acquisition includes the intellectual property and other rights in the moulds and associated tooling used in the manufacture of the adult sizes of the LMA Supreme™ and has been transacted pursuant to Resolution 10 'Shareholders Mandate' approved at LMA's Annual Meeting held on 27 April 2006, and in accordance with the terms and procedures detailed in the Appendix to the 'Letter to Shareholders' dated 5 April 2006, outlined in LMA's 2005 Annual Report.

The audit committee is of the view that the terms of the transaction are on normal commercial terms and are not prejudicial to the interests of LMA's shareholders.

- Ends -

LMA International NV

PO Box 862, Osprey House, Old Street, Jersey, Channel Islands JE4 2ZZ

Venner Capital SA

Incorporated in Panama, Venner is the holding company for the companies involved in the manufacture and research and development of the laryngeal mask products for sale to LMA. Previous products purchased from Venner include the LMA CTrach™ and the LMA Unique™. Venner is owned by Bird Island Trust, of which LMA Group Chairman Robert Gaines-Cooper is the sole beneficiary and protector under the trust. Mr Gaines-Cooper is married to Jane Gaines-Cooper, a director of LMA.

LMA International NV

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.